Impact of Pentoxifylline and Vitamin E on Ribavirin-Induced Anaemia in Chronic Hepatitis C Patients
Author Information
Author(s): M. Assem, Yousri M.
Primary Institution: National Liver Institute, Monoufiya University
Hypothesis
The study evaluates the impact of combined pentoxifylline and high-dose vitamin E on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients.
Conclusion
Pentoxifylline and vitamin E can reduce ribavirin-associated haemolysis and improve treatment adherence and virological response.
Supporting Evidence
- The combined group had significantly fewer patients needing ribavirin dose modifications due to anemia.
- Both end-of-treatment response and sustained virological response rates were higher in the combined group compared to the control group.
- No significant complications related to the added treatments were recorded.
Takeaway
This study found that adding pentoxifylline and vitamin E to hepatitis C treatment helps prevent anemia caused by ribavirin, making it easier for patients to stick to their treatment.
Methodology
A randomized controlled trial with 200 chronic hepatitis C patients receiving either standard antiviral therapy plus pentoxifylline and vitamin E or standard therapy plus placebo.
Potential Biases
Potential biases may arise from the single-blind design and the specific demographic of participants.
Limitations
The study was limited to a specific population in Egypt and may not be generalizable to other populations.
Participant Demographics
Patients were chronic hepatitis C genotype 4 Egyptian individuals aged 18 to 50 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website